Drugs /

valacyclovir

Back to Drugs List

Overview

Trade Name(s):
Valtrex
NCI Definition [1]:
The hydrochloride salt of the L-valyl ester of the antiviral drug acyclovir. Orally administered, valacyclovir is rapidly converted to acyclovir which inhibits viral DNA replication after further conversion to the nucleotide analog acyclovir triphosphate by viral thymidine kinase, cellular guanyl cyclase, and a number of other cellular enzymes. Acyclovir triphosphate competitively inhibits viral DNA polymerase; incorporates into and terminates the growing viral DNA chain; and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against herpes simplex virus (HSV) compared with varicella-zoster virus (VZV) is due to its more efficient phosphorylation by HSV thymidine kinase.

Clinical Trials

View Clinical Trials for valacyclovir

Valacyclovir has been investigated in 10 clinical trials, of which 9 are open and 1 is closed. Of the trials investigating valacyclovir, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for valacyclovir clinical trials.

Non-small cell lung carcinoma, prostate carcinoma, and anaplastic astrocytoma are the most common diseases being investigated in valacyclovir clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Valacyclovir
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Valacyclovir
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating valacyclovir and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
l-valine, 2-((2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)methoxy)ethyl ester, valaciclovirum, valacyclovir (substance), valaciclovir product, valacyclovir, valaciclovir, valacyclovir [chemical/ingredient], valacyclovir, valacyclovir product (product), l-valine ester with 9-((2-hydroxyethoxy)methyl)guanine, valacyclovir, valacyclovir product, valaciclovir, zelitrex, Valtrex
NCIT ID [1]:
C28235
SNOMED ID [1]:
C-55B18

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.